CytoMed Therapeutics Limited Financial Assets At Amortised Cost
CytoMed Therapeutics Limited (GDTC) had Financial Assets At Amortised Cost of SGD 2.74 million as of 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Notes
ifrs-full:FinancialAssetsAtAmortisedCost · last filed 2026-03-31
- 2025-12-31: Financial Assets At Amortised Cost 2.74M SGD.
- 2024-12-31: Financial Assets At Amortised Cost 5.62M SGD.
- 2023-12-31: Financial Assets At Amortised Cost 9.25M SGD; Financial Assets At Amortised Cost as first filed 9.26M SGD.
- 2022-12-31: Financial Assets At Amortised Cost 1.65M SGD.
| Period end | Financial Assets At Amortised Cost | Financial Assets At Amortised Cost as first filed |
|---|---|---|
| 2025-12-31 | 2.74M SGD 20-F · filed 2026-03-31 | |
| 2024-12-31 | 5.62M SGD 20-F · filed 2026-03-31 | |
| 2023-12-31 | 9.25M SGD 20-F · filed 2026-03-31 | 9.26M SGD 20-F · filed 2024-04-22 |
| 2022-12-31 | 1.65M SGD 20-F · filed 2025-04-28 | |
| 2021-12-31 | 2.53M SGD 20-F · filed 2024-04-22 | |
| 2020-12-31 | 940.79K SGD 20-F · filed 2023-05-01 |